NBIX•benzinga•
Neurocrine Biosciences Announces Initiation Of Phase 1 Study For NBI-1140675, A Second-Generation VMAT2 Inhibitor, In Healthy Adults For Neurological And Neuropsychiatric Conditions
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 5, 2025 by benzinga